Desmopressin in Cardiac Surgery

Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00337766

Enrollment

Unknown

Registered

2006-06-16

Start date

2006-06-30

Completion date

2010-09-30

Last updated

2015-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage, Blood Loss, Surgical, Postoperative Hemorrhage

Keywords

Blood Loss, Postoperative Blood loss

Brief summary

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products. Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Interventions

DRUGDesmopressin (DDAVP)

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* undergoing cardiac surgery * excessive bleeding

Exclusion criteria

* age\<18 y * not signing written consent

Design outcomes

Primary

Measure	Time frame
Reduce transfusions	—

Secondary

Measure	Time frame
Reduced bleeding	—
Reduce time on mechanical ventilation	—
Reduced ICU and Hospital stay	—
Reduced mortality	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026